Lung Cancer—Non-Small Cell Metastatic
LUNG CANCER—NON-SMALL CELL METASTATIC 9500 Oral Abstract Session, Fri, 8:00 AM-11:00 AM Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. Suresh S. Ramalingam, Tudor Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Michael Schenker, Reyes Bernabe Caro, Ki Hyeong Lee, Bogdan Zurawski, Clarisse Audigier-Valette, Mariano Provencio, Helena Linardou, Sang-We Kim, Hossein Borghaei, Matthew David Hellmann, Kenneth John O’Byrne, Luis G. Paz-Ares, Martin Reck, Faith Ellen Nathan, Julie R. Brahmer; Winship Cancer Institute, Emory University, Atlanta, GA; Institutul oncologic Orif Dr Ion Chiricuta and UNF Iulia Hatieganu, Cluj Napoca, Romania; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Seoul National University Bundang Hospital, Seongnam, South Korea; SF. Nectarie Oncology Center, Craiova, Romania; Hospital Universitario Virgen Del Rocio, Seville, Spain; Chungbuk National Uni- versity Hospital, Cheongju, Chungbuk, South Korea; Ambulatorium Chemioterapii, Bydgoszcz, Poland; Hopitalˆ Sainte Musse, Toulon, France; Hosp. Univ. Puerta de Hierro, Madrid, Spain; Metropolitan Hospital, Athens, Greece; Asan Medical Center, Seoul, Korea, Republic of (South); Fox Chase Cancer Center, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Princess Alexandra Hospital, Brisbane, Australia; Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense & CiberOnc, Madrid, Spain; Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Bristol-Myers Squibb, Princeton, NJ; Sidney Kimmel Com- prehensive Cancer Center at Johns Hopkins, Baltimore, MD Background: In the phase 3 CheckMate 227 Part 1 (NCT02477826; minimum follow-up, 29.3 mo), 1L NIVO + IPI significantly improved overall survival (OS) vs chemo in treatment-naive patients (pts) with aNSCLC and tumor PD-L1 expression $ 1% (primary analysis) or , 1% (pre-specified descriptive analysis).
[Show full text]